𝐈𝐧 𝟎𝟑-𝐌𝐚𝐲-𝟐𝟎𝟐𝟐 The (𝐅𝐃𝐀) has approved 2 𝐕𝐎𝐍𝐎𝐏𝐑𝐀𝐙𝐀𝐍-based medications for the treatment of Helicobacter pylori (H. pylori) infection.
The approval of 𝐕𝐎𝐍𝐎𝐏𝐑𝐀𝐙𝐀𝐍 treatment regimens offers physicians and patients 2 therapeutic options that showed superior eradication rates compared to proton pump inhibitor-based (PPI) lansoprazole triple therapy in the overall patient population in a pivotal trial.
𝐕𝐎𝐍𝐎𝐏𝐑𝐀𝐙𝐀𝐍 belongs to a class of products known as PCAB, or potassium-competitive acid blockers. By blocking the potassium-binding site of gastric hydrogen potassium ATPase (also known as the proton pump), which is the enzyme largely responsible for acidification of the stomach, it’s designed to overcome many of the perceived weaknesses of traditional proton pump inhibitor therapy.
As per its commitment to offer the latest treatment for the Egyptian's patients., in Jan 2022 Zeta Pharma was the first Egyptian pharmaceutical company to introduce two concentrations of 10mg and 20 mg of vonoprazan in the Egyptian market through its brand Vonseca.®
About Zeta Pharma
ZETA PHARMA® was established in 2010 to represent an added value in the pharmaceutical industry in Egypt through: Establishing one of the best manufacturing facilities in the Middle East referenced by the international standards (GMP). Building a well selected and unique product portfolio in the main therapeutic areas, which ensure that community has the most efficient and up-to-date treatment that directly contributes to improving health care and quality of their life.
Beginning in 2015, ZETA PHARMA® actively contribute to treating Hepatitis C virus in Egypt through its products: Sofocivir ™, Zetaciver™, Sofocivir plus™